Brought to you by 
Clovis and Ventana work on companion diagnostic
15 Mar 2013
Executive Summary
Clovis Oncology Inc. (cancer therapeutics and diagnostics) and Roche's Ventana Medical Systems Inc. (testing instruments and reagents) will develop a new immunohistochemistry (IHC) assay to be used with Clovis's investigational pancreatic cancer compound CO-1.01.
Deal Industry
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clovis and Ventana work on companion diagnostic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice